Vimarsana
Biggest News Aggregation in the World

Source Dnatrix Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Source Dnatrix Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Source Dnatrix Inc Today - Breaking & Trending Today

DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting - Vimarsana News

DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting

/PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that data from the Phase 1 study of DNX-2401 in...

DNAtrix to Present at the Raymond James Human Health Innovations Conference - Vimarsana News

DNAtrix to Present at the Raymond James Human Health Innovations Conference

DNAtrix to Present at the Raymond James Human Health Innovations Conference News provided by Share this article Share this article HOUSTON, June 9, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that the company will present at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021, at 1:20 pm ET. A live webcast of the presentation is available for access in the Newsroom section of DNAtrix's website at https://www.dnatrix.com/newsroom/. An archived replay of the presentation will be available for 30 d...

DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis - Vimarsana News

DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis

Share this article Share this article HOUSTON, March 4, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment. "We are excited to clinically explore the pot...